PT  - JOURNAL ARTICLE
AU  - Nikiforuk, Aidan M.
AU  - Kuchinski, Kevin S.
AU  - Short, Katy
AU  - Roman, Susan
AU  - Irvine, Mike A.
AU  - Prystajecky, Natalie
AU  - Jassem, Agatha N.
AU  - Patrick, David M.
AU  - Sekirov, Inna
TI  - Nasopharyngeal Angiotensin Converting Enzyme 2 (ACE2) Expression as a Risk-Factor for SARS-CoV-2 Transmission in Concurrent Hospital Associated Outbreaks
AID  - 10.1101/2023.03.20.23287264
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.03.20.23287264
4099  - http://medrxiv.org/content/early/2023/03/21/2023.03.20.23287264.short
4100  - http://medrxiv.org/content/early/2023/03/21/2023.03.20.23287264.full
AB  - Background Widespread human-to-human transmission of the severe acute respiratory syndrome coronavirus two (SARS-CoV-2) stems from a strong affinity for the cellular receptor angiotensin converting enzyme two (ACE2). We investigate the relationship between a patient’s nasopharyngeal ACE2 transcription and secondary transmission within a series of concurrent hospital associated SARS-CoV-2 outbreaks in British Columbia, Canada.Methods Epidemiological case data from the outbreak investigations was merged with public health laboratory records and viral lineage calls, from whole genome sequencing, to reconstruct the concurrent outbreaks using infection tracing transmission network analysis. ACE2 transcription and RNA viral load were measured by quantitative real-time polymerase chain reaction. The transmission network was resolved to calculate the number of potential secondary cases. Bivariate and multivariable analyses using Poisson and Negative Binomial regression models was performed to estimate the association between ACE2 transcription the number of SARS-CoV-2 secondary cases.Results The infection tracing transmission network provided n = 76 potential transmission events across n = 103 cases. Bivariate comparisons found that on average ACE2 transcription did not differ between patients and healthcare workers (P = 0.86). High ACE2 transcription was observed in 98.6% of transmission events, either the primary or secondary case had above average ACE2. Multivariable analysis found that the association between ACE2 transcription and the number of secondary transmission events differs between patients and healthcare workers. In health care workers Negative Binomial regression estimated that a one unit change in ACE2 transcription decreases the number of secondary cases (B = -0.132 (95%CI: -0.255 to -0.0181) adjusting for RNA viral load. Conversely, in patients a one unit change in ACE2 transcription increases the number of secondary cases (B = 0.187 (95% CI: 0.0101 to 0.370) adjusting for RNA viral load. Sensitivity analysis found no significant relationship between ACE2 and secondary transmission in health care workers and confirmed the positive association among patients.Conclusion Our study suggests that ACE2 transcription has a positive association with SARS-CoV-2 secondary transmission in admitted inpatients, but not health care workers in concurrent hospital associated outbreaks, and it should be further investigated as a risk-factor for viral transmission.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Canadian Institutes of Health Research (#434951) and Genome British Columbia (COV-55).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for the study was sought from the University of British Columbia human ethics board (#H20-01110) which was harmonized with the Fraser Health Authority. Written informed consent was not required. All data was de-identified prior to analysis and the results were not linked back to any identifying records. This study was deemed as minimal risk to the participants involved. To ensure privacy the site of the outbreak series will not be disclosed.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe de-identified participant data that support the findings of this study are available from the British Columbia Ministry of Health. Restrictions apply to the availability of these data, which were used under agreement at the British Columbia Center for Disease Control for this study.